A composition for the treatment of UTIs comprising: One of, a monosaccharide L-arabinose, L-frucose, D-mannose, L-rhamnose, L-xylose, lyxose or galactose; Extract from one of Boswellia serrata, Boswellia sacra or Boswellia carteri containing boswellic acids, terpenes and incensole acetate; Extract from the seeds of one of, Cucurbitaceae maxima, Cucurbitaceae pepo or Cucurbitaceae moschata; Turmeric extract; Green tea extract containing polyphenolic catechins; and, Piper nigrum.

The present invention relates to a A bactericidal or bacteriostatic composition comprising an acetal or a hexitan ether preferentially of a long-chain alkyl sorbitan, arlitan or mannitan, its use in the treatment or prevention of Gram-positive bacterial infections, its use as a hygiene or dermatological product for external use and a method for disinfecting surfaces.

The present invention relates to a A bactericidal or bacteriostatic composition comprising an acetal or a hexitan ether preferentially of a long-chain alkyl sorbitan, arlitan or mannitan, its use in the treatment or prevention of Gram-positive bacterial infections, its use as a hygiene or dermatological product for external use and a method for disinfecting surfaces.

Compositions for the treatment of shock, autodigestion, multi-organ failure, intestinal ischemia, or intestinal hypoperfusion are provided.

Compositions for the treatment of shock, autodigestion, multi-organ failure, intestinal ischemia, or intestinal hypoperfusion are provided.

Compositions for the treatment of shock, autodigestion, multi-organ failure, intestinal ischemia, or intestinal hypoperfusion are provided.

Methods for treatment of infections, such as nasal infections, sinus infections, ear infections, and/or lung infections, along with related compositions. In some implementations, a treatment method may comprise delivering a dose of the composition into a subject's nasal passage to treat the infection. The composition may comprise an antibiotic agent, such as ciprofloxacin. The composition may further comprise at least one non-hexose, sugar alcohol, such as xylitol. Preferably, the dose comprises a sub-clinical dose of the ciprofloxacin or other antibiotic agent.

Methods for treatment of infections, such as nasal infections, sinus infections, ear infections, and/or lung infections, along with related compositions. In some implementations, a treatment method may comprise delivering a dose of the composition into a subject's nasal passage to treat the infection. The composition may comprise an antibiotic agent, such as ciprofloxacin. The composition may further comprise at least one non-hexose, sugar alcohol, such as xylitol. Preferably, the dose comprises a sub-clinical dose of the ciprofloxacin or other antibiotic agent.

A method for inhibiting hair growth in mammals using compositions containing FP receptor antagonists (e.g., prostaglandin F analogs that are block activation of the FP receptor). The compositions can be applied topically to the skin and/or hair. The compositions can arrest hirsutism or hypertrichosis, reverse hirsutism and hypertrichosis, and further prevent hair growth. These compositions can also be used to protect hair from chemical or radiation-induced alopecia or hair loss. These compositions can also be used to inhibit pigmentation of the hair or skin.

A method for inhibiting hair growth in mammals using compositions containing FP receptor antagonists (e.g., prostaglandin F analogs that are block activation of the FP receptor). The compositions can be applied topically to the skin and/or hair. The compositions can arrest hirsutism or hypertrichosis, reverse hirsutism and hypertrichosis, and further prevent hair growth. These compositions can also be used to protect hair from chemical or radiation-induced alopecia or hair loss. These compositions can also be used to inhibit pigmentation of the hair or skin.